NASDAQ$STOK

Stoke Therapeutics Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Reports in 4 weeks

Stoke Therapeutics hasn't published Q2 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2026

    Revenue
    $6.23M
    EPS
    -$0.79
  • Year-ago · Q2 2024

    Q2 2024

    Revenue
    $4.83M
    EPS
    -$0.46
  • FY2025 consensus

    Analyst consensus

    Revenue
    $53.8M
    EPS
    -$1.79

Revenue & EPS history

Stoke Therapeutics · Revenue · Quarterly

$6.23M

Q1 2026-96.1%vs Q1 2025
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Historical revenue by segment

Stoke Therapeutics · $3.27M total across 1 segment · Q4 2022

  • Acadia Pharm.
    $3.27M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+4.2%

Avg return

Earnings day

+4.9%

Avg return

5 days after

+3.1%

Avg return

30 days after

48%

13 / 27 earnings

Positive

+63.3%

Q4 2023

Best reaction

-20.0%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-2.6%-9.8%
Q4 2025-2.8%-1.3%+4.1%
Q3 2025-10.1%-11.7%+21.8%
Q1 2025+1.2%-1.6%+19.7%
Q4 2024-1.4%-9.4%-14.6%
Q3 2024+1.1%+6.0%-4.0%
Q2 2024-0.6%+1.5%+3.3%
Q1 2024-0.7%-4.5%+36.5%
Q4 2023+63.3%+114.3%+85.1%
Q3 2023+7.0%-1.2%+6.7%
Q2 2023-9.3%-11.1%-13.4%
Q1 2023+25.9%+28.1%+28.2%
Q4 2022+4.5%-1.0%-10.1%
Q3 2022-20.0%-35.9%-32.9%
Q2 2022+31.7%+28.6%-10.8%
Q1 2022+2.0%+17.3%+0.6%
Q4 2021-1.6%-2.1%+9.8%
Q3 2021+3.0%+9.4%-20.2%
Q2 2021-1.4%-2.4%-1.6%
Q1 2021+11.3%+9.9%+26.6%
Q4 2020+6.8%+1.5%-30.2%
Q3 2020-0.5%-7.8%+14.6%
Q2 2020+4.7%+8.5%+18.6%
Q1 2020+15.3%+18.9%-6.0%
Q4 2019-3.9%-2.3%-6.5%
Q3 2019-11.1%-21.7%-20.0%
Q2 2019+0.0%+5.3%-11.4%
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro